(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/069520 A1

(51) International Patent Classification:
A61K 47/55 (2017.01) *A61P 35/00* (2006.01)
A61K 47/54 (2017.01)

(21) International Application Number:
PCT/EP2021/076752

(22) International Filing Date:
29 September 2021 (29.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/085,384 30 September 2020 (30.09.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85 Södertälje (SE).

(72) Inventors: **BŐRJESSON, Ulf**; ASTRAZENECA AB, 151 85 Södertälje (SE). **PERRY, Matthew, William, Dampier**; ASTRAZENECA AB, 151 85 Södertälje (SE). **GREBNER, Christoph**; ASTRAZENECA AB, 151 85 Södertälje (SE). **MICHAELIDES, Iacovos, Neal**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **HAYHOW, Thomas, George, Christopher**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **KETTLE, Jason, Grant**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **COLLIE, Gavin, William**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **STORER, Robert, Ian**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **BAGAL, Sharanjeet, Kaur**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **FALLAN, Charlene**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

(54) Title: COMPOUNDS AND THEIR USE IN TREATING CANCER



(I)

(57) Abstract: The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where A, Z, Y, RA, Linker and v have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts thereof in methods of treatment of the human or animal body, for example in the prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

WO 2022/069520 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*